[Comparison of hormone therapy alone and in combination with chemotherapy of cisplatin and methotrexate in newly diagnosed patients with stage D2 prostatic cancer].
BACKGROUND
Prognosis of hormone-refractory prostatic cancer is dismal. We evaluated the efficacy of cytotoxic chemotherapy in combination with hormone therapy in patients with newly diagnosed metastatic prostatic cancer.


METHODS
From February 1984 to March 1992, 39 newly diagnosed patients with stage D2 prostatic cancer were randomized to orchiectomy plus diethylistilbestrol diphosphate or orchiectomy plus diethylstilbestrol diphosphate plus combination chemotherapy with cisplatin and methotrexate.


RESULTS
There was not significant difference in survival or progression-free survival between the two groups.


CONCLUSIONS
Chemotherapy has not been proved to prolong survival or progression-free survival in patients who received hormone therapy.
Komatus
H
H
Department of Urology, Yamanashi Medical University, Japan.
Maesawa
H
H
Tanabe
N
N
Tago
K
K
Ueno
A
A
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
D004054:Diethylstilbestrol; C004955:fosfestrol; D002945:Cisplatin; D008727:Methotrexate